Rohit Marawar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rohit Marawar has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Maysaa Merhi Basha
Wayne State University
6 shared publications - Deepti Zutshi
Department of Neurology, Wayne State University School of Medicine, Detroit, MI, USA
4 shared publications - Aashit Shah
Wayne State Univ Health Center Detroit MI United States
2 shared publications Advait Mahulikar
Department of neurology, Wayne State University/Detroit Medical Center, University Health Center, 4201 St Antoine Ave, Detroit, MI, 4820, USA
2 shared publications- Arshdeep Kaur
Department of Neurology, Wayne State University School of Medicine, Detroit, MI, United States
2 shared publications - Bowen Song
Department of Neurology, Wayne State University School of Medicine, Detroit, MI, United States
2 shared publications
Latest Publications
- 23 June 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (12) , e218207
NeurAnki: Behind the Scenes of Creating the First-Ever Flashcard Based Deck for Resident Education (P12-5.009)
- 23 June 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (12) , e218207
NeurAnki: Behind the Scenes of Creating the First-Ever Flashcard Based Deck for Resident Education (P12-5.009)
- Open Access
- 11 October 2025
- Published by Elsevier in Epilepsy & Behavior Reports
- Vol. 32, 100833
Long-term efficacy and safety of perampanel in patients aged 60 years and older with focal seizures: Post hoc analysis of phase III open-label extension studies stratified by enzyme-inducing anti-seizure medication use
- 11 October 2025
- Published by Elsevier in Epilepsy & Behavior Reports
- Vol. 32, 100833
Open AccessLong-term efficacy and safety of perampanel in patients aged 60 years and older with focal seizures: Post hoc analysis of phase III open-label extension studies stratified by enzyme-inducing anti-seizure medication use
- Open Access
- 17 July 2025
- Published by SAGE Publications in Epilepsy Currents
- Vol. 25 (5) , 329-331
Quiet, Please—The Brain is Buzzing: Levetiracetam and the Paradox of (Fast) Ripples in Alzheimer's Disease
High-Frequency Oscillations in Epileptic and Non-Epileptic Alzheimer’s Disease Patients and the Differential Effect of Levetiracetam on the Oscillations Shandilya MCV, Addo-Osafo K, Ranasinghe KG, Shamas M, Staba R, Nagarajan SS, Vossel K. Brain Commun . 2025;7(1):fcaf041. doi:10.1093/braincomms/fcaf041 Alzheimer's disease increases the risk of developing epilepsy together with cognitive decline. Early diagnosis or prediction of parameters associated with epileptic activity can greatly help in managing disease outcomes. Network hyperexcitability is a candidate of interest as a neurophysiological biomarker of Alzheimer's disease. High-frequency oscillations are increasingly recognized as potential biomarkers of hyperexcitability and epileptic activity. However, they have not yet been identified in Alzheimer's disease. In this study, we measured high-frequency oscillations via magnetoencephalography recordings in Alzheimer's disease patients with and without epileptic activity, as part of a Phase 2a randomized, double blind clinical trial of the efficacy of levetiracetam to improve cognitive functions in Alzheimer's disease. To measure the high-frequency oscillations, we used 10-min magnetoencephalography recordings (275-channel and sampling rate 1200-4000 Hz) during awake resting periods in participants with Alzheimer's disease and healthy controls. Recordings from 14 Alzheimer's disease participants, with six having non-epileptic Alzheimer's disease (median age: 60.8, 2 M/4 F), eight having sub-clinical epileptic activity (median age: 54.9, 5 M/3 F) and eight as control (median age: 71, 5 M/3 F), were analysed using two software scripts: Delphos and a custom-made script, for detecting high-frequency oscillations. Levetiracetam 125 mg twice-a-day or placebo was administered for 4 weeks in between two magnetoencephalography recordings, and 4 weeks of washout before switching levetiracetam/placebo phases for each participant. High-frequency oscillations were categorized into ripples (80 to 250 Hz) and fast ripples (250 to 500 Hz). At baseline, Alzheimer's disease participants, both epileptic and non-epileptic had higher rate of ripples and fast ripples than controls in several left/right hemispheric sensor regions ( P < 0.05). Additionally, compared to epileptic, non-epileptic had higher rate of ripples in left-frontal, left-temporal and cerebral fissure regions and higher rate of fast ripples in left-frontal regions ( P < 0.05). In epileptic type, levetiracetam decreased ripples in bilateral-frontal, bilateral-occipital regions and cerebral fissure, whereas in non-epileptic type, levetiracetam increased both ripples and fast ripples in right central and left parietal regions, and ripples in the right parietal region ( P < 0.05). Additionally, we found hemisphere asymmetry in epileptic type, with right temporal/occipital having more high-frequency oscillations than their counterpart region. Overall, Alzheimer's disease had a high level of high-frequency oscillations, with higher numbers observed in non-epileptic type. Levetiracetam decreased high-frequency oscillations in epileptic but increased high-frequency oscillations in non-epileptic. Thus, high-frequency oscillations can function as a biomarker of hyperexcitability in Alzheimer's disease and may be more pathological when asymmetric and coinciding with presence of epileptic activity. Levetiracetam has the potential for treating hyperactivity in patients with epileptic Alzheimer's disease.
- 17 July 2025
- Published by SAGE Publications in Epilepsy Currents
- Vol. 25 (5) , 329-331
Open AccessQuiet, Please—The Brain is Buzzing: Levetiracetam and the Paradox of (Fast) Ripples in Alzheimer's Disease
High-Frequency Oscillations in Epileptic and Non-Epileptic Alzheimer’s Disease Patients and the Differential Effect of Levetiracetam on the Oscillations Shandilya MCV, Addo-Osafo K, Ranasinghe KG, Shamas M, Staba R, Nagarajan SS, Vossel K. Brain Commun . 2025;7(1):fcaf041. doi:10.1093/braincomms/fcaf041 Alzheimer's disease increases the risk of developing epilepsy together with cognitive decline. Early diagnosis or prediction of parameters associated with epileptic activity can greatly help in managing disease outcomes. Network hyperexcitability is a candidate of interest as a neurophysiological biomarker of Alzheimer's disease. High-frequency oscillations are increasingly recognized as potential biomarkers of hyperexcitability and epileptic activity. However, they have not yet been identified in Alzheimer's disease. In this study, we measured high-frequency oscillations via magnetoencephalography recordings in Alzheimer's disease patients with and without epileptic activity, as part of a Phase 2a randomized, double blind clinical trial of the efficacy of levetiracetam to improve cognitive functions in Alzheimer's disease. To measure the high-frequency oscillations, we used 10-min magnetoencephalography recordings (275-channel and sampling rate 1200-4000 Hz) during awake resting periods in participants with Alzheimer's disease and healthy controls. Recordings from 14 Alzheimer's disease participants, with six having non-epileptic Alzheimer's disease (median age: 60.8, 2 M/4 F), eight having sub-clinical epileptic activity (median age: 54.9, 5 M/3 F) and eight as control (median age: 71, 5 M/3 F), were analysed using two software scripts: Delphos and a custom-made script, for detecting high-frequency oscillations. Levetiracetam 125 mg twice-a-day or placebo was administered for 4 weeks in between two magnetoencephalography recordings, and 4 weeks of washout before switching levetiracetam/placebo phases for each participant. High-frequency oscillations were categorized into ripples (80 to 250 Hz) and fast ripples (250 to 500 Hz). At baseline, Alzheimer's disease participants, both epileptic and non-epileptic had higher rate of ripples and fast ripples than controls in several left/right hemispheric sensor regions ( P < 0.05). Additionally, compared to epileptic, non-epileptic had higher rate of ripples in left-frontal, left-temporal and cerebral fissure regions and higher rate of fast ripples in left-frontal regions ( P < 0.05). In epileptic type, levetiracetam decreased ripples in bilateral-frontal, bilateral-occipital regions and cerebral fissure, whereas in non-epileptic type, levetiracetam increased both ripples and fast ripples in right central and left parietal regions, and ripples in the right parietal region ( P < 0.05). Additionally, we found hemisphere asymmetry in epileptic type, with right temporal/occipital having more high-frequency oscillations than their counterpart region. Overall, Alzheimer's disease had a high level of high-frequency oscillations, with higher numbers observed in non-epileptic type. Levetiracetam decreased high-frequency oscillations in epileptic but increased high-frequency oscillations in non-epileptic. Thus, high-frequency oscillations can function as a biomarker of hyperexcitability in Alzheimer's disease and may be more pathological when asymmetric and coinciding with presence of epileptic activity. Levetiracetam has the potential for treating hyperactivity in patients with epileptic Alzheimer's disease.
- 27 June 2025
- Published by Wiley in Epileptic Disorders
- Vol. 27 (4) , 629-641
Latency to presentation after seizure onset and drug resistance to a comprehensive epilepsy center in an urban tertiary care center
Objective: To evaluate latency to presentation among persons with epilepsy at an urban National Association of Epilepsy Centers Level IV epilepsy center and assess the impact of socioeconomic status and race on this latency. Less than 1% of persons with epilepsy are referred to specialized centers in the United States, often taking over twenty years to undergo surgery, significantly affecting quality of life and healthcare costs. Our primary objective was to assess latency to presentation at our Level IV epilepsy clinic in Detroit, Michigan. The secondary objective was to evaluate the impact of low socioeconomic status and Black race on latency to presentation.Methods: We retrospectively analyzed persons with epilepsy seen at our clinic in 2014, excluding those previously seen at an epilepsy center. Persons with epilepsy were divided into drug‐resistant epilepsy and non‐drug‐resistant epilepsy groups. We calculated latency to presentation for all patients and both groups and assessed drug resistance for the drug‐resistant epilepsy group. Regression models were fitted using latency to presentation as the outcome variable.Results: A total of 648 unique persons with epilepsy were seen, with 408 included in the analysis. Among these, 66.42% were Black, and 63.72% had low socioeconomic status. The drug‐resistant epilepsy group had more patients with known etiology and temporal lobe epilepsy (p < 0.05). The mean latency to presentation was 13.21 years for all patients and 16.04 years for the drug‐resistant epilepsy group; since drug resistance, it was 14.74 years. Persons with low socioeconomic status showed longer latency, but significance did not persist after regression. No differences were found between Black and White persons.Significance: Optimal epilepsy care in the United States remains delayed with first presentation to the epilepsy clinic taking more than 13 years. Future studies should explore reasons for these delays rather than focusing solely on epilepsy surgery referrals.
- 27 June 2025
- Published by Wiley in Epileptic Disorders
- Vol. 27 (4) , 629-641
Latency to presentation after seizure onset and drug resistance to a comprehensive epilepsy center in an urban tertiary care center
Objective: To evaluate latency to presentation among persons with epilepsy at an urban National Association of Epilepsy Centers Level IV epilepsy center and assess the impact of socioeconomic status and race on this latency. Less than 1% of persons with epilepsy are referred to specialized centers in the United States, often taking over twenty years to undergo surgery, significantly affecting quality of life and healthcare costs. Our primary objective was to assess latency to presentation at our Level IV epilepsy clinic in Detroit, Michigan. The secondary objective was to evaluate the impact of low socioeconomic status and Black race on latency to presentation.Methods: We retrospectively analyzed persons with epilepsy seen at our clinic in 2014, excluding those previously seen at an epilepsy center. Persons with epilepsy were divided into drug‐resistant epilepsy and non‐drug‐resistant epilepsy groups. We calculated latency to presentation for all patients and both groups and assessed drug resistance for the drug‐resistant epilepsy group. Regression models were fitted using latency to presentation as the outcome variable.Results: A total of 648 unique persons with epilepsy were seen, with 408 included in the analysis. Among these, 66.42% were Black, and 63.72% had low socioeconomic status. The drug‐resistant epilepsy group had more patients with known etiology and temporal lobe epilepsy (p < 0.05). The mean latency to presentation was 13.21 years for all patients and 16.04 years for the drug‐resistant epilepsy group; since drug resistance, it was 14.74 years. Persons with low socioeconomic status showed longer latency, but significance did not persist after regression. No differences were found between Black and White persons.Significance: Optimal epilepsy care in the United States remains delayed with first presentation to the epilepsy clinic taking more than 13 years. Future studies should explore reasons for these delays rather than focusing solely on epilepsy surgery referrals.
- Open Access
- 21 November 2024
- Published by SAGE Publications in Epilepsy Currents
- Vol. 25 (1) , 29-31
Late-Onset Temporal Lobe Epilepsy—Differentiating the Gray Matter from the Matter of Gray
Considering the growing age of the world population, the incidence of epilepsy in older adults is expected to increase significantly. It has been suggested that late-onset temporal lobe epilepsy (LO-TLE) may be neurodegenerative in origin and overlap with Alzheimer's disease (AD). Herein, we aimed to characterize the pattern of cortical atrophy and cerebrospinal fluid (CSF) biomarkers of AD (total and phosphorylated tau, and β-amyloid) in a selected population of LO-TLE of unknown origin. We prospectively enrolled individuals with temporal lobe epilepsy onset after the age of 50 and no cognitive impairment. They underwent a structural MRI scan and CSF biomarkers measurement. Imaging and biomarkers data were compared to 3 retrospectively collected groups: (i) age- and sex-matched healthy controls, (ii) patients with mild cognitive impairment (MCI) and abnormal CSF AD biomarkers (MCI-AD), and (iii) patients with MCI and normal CSF AD biomarkers (MCI-noAD). From a pool of 52 patients, 20 consecutive eligible LO-TLE patients with a mean disease duration of 1.8 years were recruited. As control populations, 25 patients with MCI-AD, 25 patients with MCI-noAD, and 25 healthy controls were enrolled. CSF biomarkers returned normal values in LO-TLE, significantly different from patients with MCI due to AD. There were no differences in cortico-subcortical atrophy between epilepsy patients and healthy controls, while patients with MCI demonstrated widespread injuries of cortico-subcortical structures. Individuals with a late-onset form of temporal lobe epilepsy, characterized by short disease duration and normal CSF β-amyloid and tau protein levels, showed patterns of cortical thickness and subcortical volumes not significantly different from healthy controls, but highly different from patients with MCI, either due to AD or not.
- 21 November 2024
- Published by SAGE Publications in Epilepsy Currents
- Vol. 25 (1) , 29-31
Open AccessLate-Onset Temporal Lobe Epilepsy—Differentiating the Gray Matter from the Matter of Gray
Considering the growing age of the world population, the incidence of epilepsy in older adults is expected to increase significantly. It has been suggested that late-onset temporal lobe epilepsy (LO-TLE) may be neurodegenerative in origin and overlap with Alzheimer's disease (AD). Herein, we aimed to characterize the pattern of cortical atrophy and cerebrospinal fluid (CSF) biomarkers of AD (total and phosphorylated tau, and β-amyloid) in a selected population of LO-TLE of unknown origin. We prospectively enrolled individuals with temporal lobe epilepsy onset after the age of 50 and no cognitive impairment. They underwent a structural MRI scan and CSF biomarkers measurement. Imaging and biomarkers data were compared to 3 retrospectively collected groups: (i) age- and sex-matched healthy controls, (ii) patients with mild cognitive impairment (MCI) and abnormal CSF AD biomarkers (MCI-AD), and (iii) patients with MCI and normal CSF AD biomarkers (MCI-noAD). From a pool of 52 patients, 20 consecutive eligible LO-TLE patients with a mean disease duration of 1.8 years were recruited. As control populations, 25 patients with MCI-AD, 25 patients with MCI-noAD, and 25 healthy controls were enrolled. CSF biomarkers returned normal values in LO-TLE, significantly different from patients with MCI due to AD. There were no differences in cortico-subcortical atrophy between epilepsy patients and healthy controls, while patients with MCI demonstrated widespread injuries of cortico-subcortical structures. Individuals with a late-onset form of temporal lobe epilepsy, characterized by short disease duration and normal CSF β-amyloid and tau protein levels, showed patterns of cortical thickness and subcortical volumes not significantly different from healthy controls, but highly different from patients with MCI, either due to AD or not.
- Open Access
- 30 October 2024
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 8, e53491
Self-Reported Patient and Provider Satisfaction With Neurology Telemedicine Visits After Rapid Telemedicine Implementation in an Urban Academic Center: Cross-Sectional Survey
Background: Many clinics and health systems implemented telemedicine appointment services out of necessity due to the COVID-19 pandemic. Objective: Our objective was to evaluate patient and general provider satisfaction with neurology telemedicine implementation at an urban academic medical center. Methods: Patients who had completed 1 or more teleneurology visits from April 1 to December 31, 2020, were asked to complete a survey regarding their demographic information and satisfaction with teleneurology visits. Providers of all specialties within the same hospital system were given a different survey to gather their experiences of providing telemedicine care. Results: Of the estimated 1500 patients who had completed a teleneurology visit within the given timeframe, 117 (7.8%) consented to complete the survey. Of these 117 respondents, most appointments were regarding epilepsy (n=59, 50.4%), followed by multiple sclerosis (n=33, 28.2%) and neuroimmunology (n=7, 6%). Overall, 74.4% (n=87) of patients rated their experience as 8 out of 10 or higher, with 10 being the highest satisfaction. Furthermore, 75.2% (n=88) of patients reported missing an appointment in the previous year due to transportation issues and thought telemedicine was more convenient instead. A significant relationship between racial or ethnic group and comfort sharing private information was found (P<.001), with 52% (26/50) of Black patients reporting that an office visit is better, compared to 25% (14/52) of non-Black patients. The provider survey gathered 40 responses, with 75% (n=30) of providers agreeing that virtual visits are a valuable tool for patient care and 80% (n=32) reporting few to no technical issues. The majority of provider respondents were physicians on faculty or staff (n=21, 52%), followed by residents or fellows (n=15, 38%) and nurse practitioners or physician assistants (n=4, 10%). Of the specialties represented, 15 (38%) of the providers were in neurology. Conclusions: Our study found adequate satisfaction among patients and providers regarding telemedicine implementation and its utility for patient care in a diverse urban population. Additionally, while access to technology and technology literacy are barriers to telemedical care, a substantial majority of patients who responded to the survey had access to devices (101/117, 86.3%) and were able to connect with few to no technological difficulties (84/117, 71.8%). One area identified by patients in need of improvement was comfortability in communicating via telemedicine with their providers. Furthermore, while providers agreed that telemedicine is a useful tool for patient care, it limits their ability to perform physical exams. More research and quality studies are needed to further appreciate and support the expansion of telemedical care into underserved and rural populations, especially in the area of subspecialty neurological care.
- 30 October 2024
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 8, e53491
Open AccessSelf-Reported Patient and Provider Satisfaction With Neurology Telemedicine Visits After Rapid Telemedicine Implementation in an Urban Academic Center: Cross-Sectional Survey
Background: Many clinics and health systems implemented telemedicine appointment services out of necessity due to the COVID-19 pandemic. Objective: Our objective was to evaluate patient and general provider satisfaction with neurology telemedicine implementation at an urban academic medical center. Methods: Patients who had completed 1 or more teleneurology visits from April 1 to December 31, 2020, were asked to complete a survey regarding their demographic information and satisfaction with teleneurology visits. Providers of all specialties within the same hospital system were given a different survey to gather their experiences of providing telemedicine care. Results: Of the estimated 1500 patients who had completed a teleneurology visit within the given timeframe, 117 (7.8%) consented to complete the survey. Of these 117 respondents, most appointments were regarding epilepsy (n=59, 50.4%), followed by multiple sclerosis (n=33, 28.2%) and neuroimmunology (n=7, 6%). Overall, 74.4% (n=87) of patients rated their experience as 8 out of 10 or higher, with 10 being the highest satisfaction. Furthermore, 75.2% (n=88) of patients reported missing an appointment in the previous year due to transportation issues and thought telemedicine was more convenient instead. A significant relationship between racial or ethnic group and comfort sharing private information was found (P<.001), with 52% (26/50) of Black patients reporting that an office visit is better, compared to 25% (14/52) of non-Black patients. The provider survey gathered 40 responses, with 75% (n=30) of providers agreeing that virtual visits are a valuable tool for patient care and 80% (n=32) reporting few to no technical issues. The majority of provider respondents were physicians on faculty or staff (n=21, 52%), followed by residents or fellows (n=15, 38%) and nurse practitioners or physician assistants (n=4, 10%). Of the specialties represented, 15 (38%) of the providers were in neurology. Conclusions: Our study found adequate satisfaction among patients and providers regarding telemedicine implementation and its utility for patient care in a diverse urban population. Additionally, while access to technology and technology literacy are barriers to telemedical care, a substantial majority of patients who responded to the survey had access to devices (101/117, 86.3%) and were able to connect with few to no technological difficulties (84/117, 71.8%). One area identified by patients in need of improvement was comfortability in communicating via telemedicine with their providers. Furthermore, while providers agreed that telemedicine is a useful tool for patient care, it limits their ability to perform physical exams. More research and quality studies are needed to further appreciate and support the expansion of telemedical care into underserved and rural populations, especially in the area of subspecialty neurological care.
- Open Access
- 1 March 2024
- Published by SAGE Publications in Epilepsy Currents
- Vol. 24 (2) , 114-116
Sleeping High and Getting Lost on the Spiky Road: What Affects Visual Memory in Older Adults With Epilepsy, and What Can We Do About It?
- 1 March 2024
- Published by SAGE Publications in Epilepsy Currents
- Vol. 24 (2) , 114-116
Open AccessSleeping High and Getting Lost on the Spiky Road: What Affects Visual Memory in Older Adults With Epilepsy, and What Can We Do About It?
- 1 January 2024
- Published by Springer Nature
- p. 225-239
Anti-Seizure Medications
- Open Access
- 13 December 2023
- Published by SAGE Publications in Epilepsy Currents
- Vol. 24 (1) , 34-36
Get Out the Door: Ambulatory EEG Trumps Routine EEG in the Detection of Interictal Epileptiform Abnormalities After a First Unprovoked Seizure
Diagnostic Accuracy of Ambulatory EEG vs Routine EEG in Patients With First Single Unprovoked Seizure Hernandez-Ronquillo L, Thorpe L, Feng C, Hunter G, Dash D, Hussein T, Dolinsky C, Waterhouse K, Roy P, Jette N. Neurol Clin Pract . 2023;13(3). doi: 10.1212/CPJ.0000000000200160 Background and Objective: To evaluate the diagnostic accuracy of the ambulatory EEG (aEEG) at detecting interictal epileptiform discharges (IEDs)/seizures compared with routine EEG (rEEG) and repetitive/second rEEG in patients with a first single unprovoked seizure (FSUS). We also evaluated the association between IED/seizures on aEEG and seizure recurrence within 1 year of follow-up. Methods: We prospectively evaluated 100 consecutive patients with FSUS at the provincial Single Seizure Clinic. They underwent 3 sequential EEG modalities: first rEEG, second rEEG, and aEEG. Clinical epilepsy diagnosis was ascertained based on the 2014 International League Against Epilepsy definition by a neurologist/epileptologist at the clinic. An EEG-certified epileptologist/neurologist interpreted all 3 EEGs. All patients were followed up for 52 weeks until they had either second unprovoked seizure or maintained single seizure status. Accuracy measures (sensitivity, specificity, negative and positive predictive values, and likelihood ratios), receiver operating characteristic (ROC) analysis, and area under the curve (AUC) were used to evaluate the diagnostic accuracy of each EEG modality. Life tables and the Cox proportional hazard model were used to estimate the probability and association of seizure recurrence. Results: Ambulatory EEG captured IED/seizures with a sensitivity of 72%, compared with 11% for the first rEEG and 22% for the second rEEG. The diagnostic performance of the aEEG was statistically better (AUC: 0.85) compared with the first rEEG (AUC: 0.56) and second rEEG (AUC: 0.60). There were no statistically significant differences between the 3 EEG modalities regarding specificity and positive predictive value. Finally, IED/seizure on the aEEG was associated with more than 3 times the hazard of seizure recurrence. Discussion: The overall diagnostic accuracy of aEEG at capturing IED/seizures in people presenting with FSUS was higher than the first and second rEEGs. We also found that IED/seizures on the aEEG were associated with an increased risk of seizure recurrence. Classification of Evidence: This study provides Class I evidence supporting that, in adults with First Single Unprovoked Seizure (FSUS), 24-h ambulatory EEG has increased sensitivity when compared with routine and repeated EEG.
- 13 December 2023
- Published by SAGE Publications in Epilepsy Currents
- Vol. 24 (1) , 34-36
Open AccessGet Out the Door: Ambulatory EEG Trumps Routine EEG in the Detection of Interictal Epileptiform Abnormalities After a First Unprovoked Seizure
Diagnostic Accuracy of Ambulatory EEG vs Routine EEG in Patients With First Single Unprovoked Seizure Hernandez-Ronquillo L, Thorpe L, Feng C, Hunter G, Dash D, Hussein T, Dolinsky C, Waterhouse K, Roy P, Jette N. Neurol Clin Pract . 2023;13(3). doi: 10.1212/CPJ.0000000000200160 Background and Objective: To evaluate the diagnostic accuracy of the ambulatory EEG (aEEG) at detecting interictal epileptiform discharges (IEDs)/seizures compared with routine EEG (rEEG) and repetitive/second rEEG in patients with a first single unprovoked seizure (FSUS). We also evaluated the association between IED/seizures on aEEG and seizure recurrence within 1 year of follow-up. Methods: We prospectively evaluated 100 consecutive patients with FSUS at the provincial Single Seizure Clinic. They underwent 3 sequential EEG modalities: first rEEG, second rEEG, and aEEG. Clinical epilepsy diagnosis was ascertained based on the 2014 International League Against Epilepsy definition by a neurologist/epileptologist at the clinic. An EEG-certified epileptologist/neurologist interpreted all 3 EEGs. All patients were followed up for 52 weeks until they had either second unprovoked seizure or maintained single seizure status. Accuracy measures (sensitivity, specificity, negative and positive predictive values, and likelihood ratios), receiver operating characteristic (ROC) analysis, and area under the curve (AUC) were used to evaluate the diagnostic accuracy of each EEG modality. Life tables and the Cox proportional hazard model were used to estimate the probability and association of seizure recurrence. Results: Ambulatory EEG captured IED/seizures with a sensitivity of 72%, compared with 11% for the first rEEG and 22% for the second rEEG. The diagnostic performance of the aEEG was statistically better (AUC: 0.85) compared with the first rEEG (AUC: 0.56) and second rEEG (AUC: 0.60). There were no statistically significant differences between the 3 EEG modalities regarding specificity and positive predictive value. Finally, IED/seizure on the aEEG was associated with more than 3 times the hazard of seizure recurrence. Discussion: The overall diagnostic accuracy of aEEG at capturing IED/seizures in people presenting with FSUS was higher than the first and second rEEGs. We also found that IED/seizures on the aEEG were associated with an increased risk of seizure recurrence. Classification of Evidence: This study provides Class I evidence supporting that, in adults with First Single Unprovoked Seizure (FSUS), 24-h ambulatory EEG has increased sensitivity when compared with routine and repeated EEG.
- Open Access
- 8 October 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Self-Reported Patient and Provider Satisfaction With Neurology Telemedicine Visits After Rapid Telemedicine Implementation in an Urban Academic Center: Cross-Sectional Survey (Preprint)
BACKGROUND Many clinics and health systems implemented telemedicine appointment services out of necessity due to the COVID-19 pandemic. OBJECTIVE Our objective was to evaluate patient and general provider satisfaction with neurology telemedicine implementation at an urban academic medical center. METHODS Patients who had completed 1 or more teleneurology visits from April 1 to December 31, 2020, were asked to complete a survey regarding their demographic information and satisfaction with teleneurology visits. Providers of all specialties within the same hospital system were given a different survey to gather their experiences of providing telemedicine care. RESULTS Of the estimated 1500 patients who had completed a teleneurology visit within the given timeframe, 117 (7.8%) consented to complete the survey. Of these 117 respondents, most appointments were regarding epilepsy (n=59, 50.4%), followed by multiple sclerosis (n=33, 28.2%) and neuroimmunology (n=7, 6%). Overall, 74.4% (n=87) of patients rated their experience as 8 out of 10 or higher, with 10 being the highest satisfaction. Furthermore, 75.2% (n=88) of patients reported missing an appointment in the previous year due to transportation issues and thought telemedicine was more convenient instead. A significant relationship between racial or ethnic group and comfort sharing private information was found (P<.001), with 52% (26/50) of Black patients reporting that an office visit is better, compared to 25% (14/52) of non-Black patients. The provider survey gathered 40 responses, with 75% (n=30) of providers agreeing that virtual visits are a valuable tool for patient care and 80% (n=32) reporting few to no technical issues. The majority of provider respondents were physicians on faculty or staff (n=21, 52%), followed by residents or fellows (n=15, 38%) and nurse practitioners or physician assistants (n=4, 10%). Of the specialties represented, 15 (38%) of the providers were in neurology. CONCLUSIONS Our study found adequate satisfaction among patients and providers regarding telemedicine implementation and its utility for patient care in a diverse urban population. Additionally, while access to technology and technology literacy are barriers to telemedical care, a substantial majority of patients who responded to the survey had access to devices (101/117, 86.3%) and were able to connect with few to no technological difficulties (84/117, 71.8%). One area identified by patients in need of improvement was comfortability in communicating via telemedicine with their providers. Furthermore, while providers agreed that telemedicine is a useful tool for patient care, it limits their ability to perform physical exams. More research and quality studies are needed to further appreciate and support the expansion of telemedical care into underserved and rural populations, especially in the area of subspecialty neurological care.
- 8 October 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessSelf-Reported Patient and Provider Satisfaction With Neurology Telemedicine Visits After Rapid Telemedicine Implementation in an Urban Academic Center: Cross-Sectional Survey (Preprint)
BACKGROUND Many clinics and health systems implemented telemedicine appointment services out of necessity due to the COVID-19 pandemic. OBJECTIVE Our objective was to evaluate patient and general provider satisfaction with neurology telemedicine implementation at an urban academic medical center. METHODS Patients who had completed 1 or more teleneurology visits from April 1 to December 31, 2020, were asked to complete a survey regarding their demographic information and satisfaction with teleneurology visits. Providers of all specialties within the same hospital system were given a different survey to gather their experiences of providing telemedicine care. RESULTS Of the estimated 1500 patients who had completed a teleneurology visit within the given timeframe, 117 (7.8%) consented to complete the survey. Of these 117 respondents, most appointments were regarding epilepsy (n=59, 50.4%), followed by multiple sclerosis (n=33, 28.2%) and neuroimmunology (n=7, 6%). Overall, 74.4% (n=87) of patients rated their experience as 8 out of 10 or higher, with 10 being the highest satisfaction. Furthermore, 75.2% (n=88) of patients reported missing an appointment in the previous year due to transportation issues and thought telemedicine was more convenient instead. A significant relationship between racial or ethnic group and comfort sharing private information was found (P<.001), with 52% (26/50) of Black patients reporting that an office visit is better, compared to 25% (14/52) of non-Black patients. The provider survey gathered 40 responses, with 75% (n=30) of providers agreeing that virtual visits are a valuable tool for patient care and 80% (n=32) reporting few to no technical issues. The majority of provider respondents were physicians on faculty or staff (n=21, 52%), followed by residents or fellows (n=15, 38%) and nurse practitioners or physician assistants (n=4, 10%). Of the specialties represented, 15 (38%) of the providers were in neurology. CONCLUSIONS Our study found adequate satisfaction among patients and providers regarding telemedicine implementation and its utility for patient care in a diverse urban population. Additionally, while access to technology and technology literacy are barriers to telemedical care, a substantial majority of patients who responded to the survey had access to devices (101/117, 86.3%) and were able to connect with few to no technological difficulties (84/117, 71.8%). One area identified by patients in need of improvement was comfortability in communicating via telemedicine with their providers. Furthermore, while providers agreed that telemedicine is a useful tool for patient care, it limits their ability to perform physical exams. More research and quality studies are needed to further appreciate and support the expansion of telemedical care into underserved and rural populations, especially in the area of subspecialty neurological care.